Saul Tzipori

List of Publications by Year
in descending order

47 papers	3,211 citations	257450 24 h-index	223800 46 g-index
47 all docs	47 docs citations	47 times ranked	3420 citing authors

#	Article	IF	Citations
1	Development of Two Mouse Models for Vaccine Evaluation against Cryptosporidiosis. Infection and Immunity, 2022, 90, .	2.2	4
2	The Impact of Actotoxumab Treatment of Gnotobiotic Piglets Infected With Different Clostridium difficile Isogenic Mutants. Journal of Infectious Diseases, 2020, 221, 276-284.	4.0	0
3	An immunocompetent rat model of infection with Cryptosporidium hominis and Cryptosporidium parvum. International Journal for Parasitology, 2020, 50, 19-22.	3.1	9
4	Cryopreservation of infectious Cryptosporidium parvum oocysts achieved through vitrification using high aspect ratio specimen containers. Scientific Reports, 2020, 10, 11711.	3.3	5
5	The piglet acute diarrhea model for evaluating efficacy of treatment and control of cryptosporidiosis. Human Vaccines and Immunotherapeutics, 2019, 15, 1445-1452.	3.3	20
6	Ingestible Osmotic Pill for In Vivo Sampling of Gut Microbiomes. Advanced Intelligent Systems, 2019, 1, 1900053.	6.1	40
7	Ingestible Osmotic Pill for In Vivo Sampling of Gut Microbiomes. Advanced Intelligent Systems, 2019, 1, 1970052.	6.1	8
8	Piperazine-Derivative MMV665917: An Effective Drug in the Diarrheic Piglet Model of Cryptosporidium hominis. Journal of Infectious Diseases, 2019, 220, 285-293.	4.0	20
9	Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
10	Infection with anthroponotic Cryptosporidium parvum does not fully protect the host against a subsequent challenge with C . hominis. Microbes and Infection, 2018, 20, 267-270.	1.9	5
11	Cryopreservation of infectious Cryptosporidium parvum oocysts. Nature Communications, 2018, 9, 2883.	12.8	19
12	The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis. PLoS ONE, 2017, 12, e0185906.	2.5	24
13	Cryptosporidium hominisgene catalog: a resource for the selection of novelCryptosporidiumvaccine candidates. Database: the Journal of Biological Databases and Curation, 2016, 2016, baw137.	3.0	11
14	A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection. Vaccine Journal, 2016, 23, 774-784.	3.1	37
15	Continuous culture of Cryptosporidium parvum using hollow fiber technology. International Journal for Parasitology, 2016, 46, 21-29.	3.1	102
16	Hyperimmune Bovine Colostrum as a Novel Therapy to Combat Clostridium difficile Infection. Journal of Infectious Diseases, 2015, 211, 1334-41.	4.0	35
17	Adenovirus Vector Expressing Stx1/Stx2-Neutralizing Agent Protects Piglets Infected with Escherichia coli O157:H7 against Fatal Systemic Intoxication. Infection and Immunity, 2015, 83, 286-291.	2.2	22
18	Willingness to Consult a Veterinarian on Physicianâ€™s Advice for Zoonotic Diseases: A Formal Role for Veterinarians in Medicine?. PLoS ONE, 2015, 10, e0131406.	2.5	14

#	Article	IF	Citations
19	Selective Evolution of Ligands by Exponential Enrichment to Identify RNA Aptamers against Shiga Toxins. Journal of Nucleic Acids, 2014, 2014, 1-8.	1.2	14
20	The roles of toxin A and toxin B inClostridium difficileinfection. Gut Microbes, 2014, 5, 53-57.	9.8	4
21	Beneficial Effect of Oral Tigecycline Treatment on Clostridium difficile Infection in Gnotobiotic Piglets. Antimicrobial Agents and Chemotherapy, 2014, 58, 7560-7564.	3.2	12
22	The immune response of two microbial antigens delivered intradermally, sublingually, or the combination thereof. Microbes and Infection, 2014, 16, 796-803.	1.9	19
23	The Evolution of Respiratory Cryptosporidiosis: Evidence for Transmission by Inhalation. Clinical Microbiology Reviews, 2014, 27, 575-586.	13.6	95
24	Systemically Administered IgG Anti-Toxin Antibodies Protect the Colonic Mucosa during Infection with Clostridium difficile in the Piglet Model. PLoS ONE, 2014, 9, e111075.	2.5	13
25	Antibody Against TcdB, but Not TcdA, Prevents Development of Gastrointestinal and Systemic Clostridium difficile Disease. Journal of Infectious Diseases, 2013, 207, 323-330.	4.0	91
26	Evaluation of virulent and live Shigella sonnei vaccine candidates in a gnotobiotic piglet model. Vaccine, 2013, 31, 4039-4046.	3.8	10
27	Hyperimmune bovine colostrum for treatment of GI infections. Human Vaccines and Immunotherapeutics, 2013, 9, 1565-1568.	3.3	61
28	A pig model of the human gastrointestinal tract. Gut Microbes, 2013, 4, 193-200.	9.8	163
29	Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets. Microbes and Infection, 2012, 14, 447-456.	1.9	21
30	Bacillus subtilis. Human Vaccines and Immunotherapeutics, 2012, 8, 979-986.	3.3	64
31	Piglet Models of Acute or ChronicClostridium difficileIllness. Journal of Infectious Diseases, 2010, 201, 428-434.	4.0	84
32	A Piglet Model of Acute Gastroenteritis Induced byShigella dysenteriaeType 1. Journal of Infectious Diseases, 2010, 201, 903-911.	4.0	38
33	Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C. Vaccine, 2010, 28, 6658-6665.	3.8	26
34	CRYPTOSPORIDIUM HOMINIS: EXPERIMENTAL CHALLENGE OF HEALTHY ADULTS. American Journal of Tropical Medicine and Hygiene, 2006, 75, 851-857.	1.4	193
35	Cryptosporidium hominis: experimental challenge of healthy adults. American Journal of Tropical Medicine and Hygiene, 2006, 75, 851-7.	1.4	72
36	Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic Syndrome. Clinical Microbiology Reviews, 2004, 17, 926-941.	13.6	105

#	Article	IF	Citations
37	The genome of Cryptosporidium hominis. Nature, 2004, 431, 1107-1112.	27.8	506
38	CRYPTOSPORIDIUM PARVUM IN CHILDREN WITH DIARRHEA IN MULAGO HOSPITAL, KAMPALA, UGANDA. American Journal of Tropical Medicine and Hygiene, 2003, 68, 710-715.	1.4	151
39	Cryptosporidium parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. American Journal of Tropical Medicine and Hygiene, 2003, 68, 710-5.	1.4	74
40	Introduction. Cryptosporidiosis: current trends and challenges. Microbes and Infection, 2002, 4, 1045.	1.9	13
41	Cryptosporidiosis: biology, pathogenesis and disease. Microbes and Infection, 2002, 4, 1047-1058.	1.9	233
42	Intestinal Lesions Associated with Disseminated Candidiasis in an Experimental Animal Model. Journal of Clinical Microbiology, 2000, 38, 2317-2323.	3.9	4
43	Shikimate pathway in apicomplexan parasites. Nature, 1999, 397, 220-220.	27.8	10
44	Î²-Tubulin mRNA as a Marker of Cryptosporidium parvum Oocyst Viability. Applied and Environmental Microbiology, 1999, 65, 1584-1588.	3.1	63
45	Evidence for the shikimate pathway in apicomplexan parasites. Nature, 1998, 393, 801-805.	27.8	436
46	Efficacy of Nitazoxanide against Cryptosporidium parvum in Cell Culture and in Animal Models. Antimicrobial Agents and Chemotherapy, 1998, 42, 1959-1965.	3.2	156
47	Transmission and Establishment of a Persistent Infection ofEnterocytozoon bieneusi, Derived from a Human with AIDS, in Simian Immunodeficiency Virusâ€"Infected Rhesus Monkeys. Journal of Infectious Diseases, 1997, 175, 1016-1020.	4.0	74